Denver D Brown1, Jennifer Roem2, Derek K Ng3, Kimberly J Reidy4, Juhi Kumar5, Matthew K Abramowitz6, Robert H Mak7, Susan L Furth8, George J Schwartz9, Bradley A Warady10, Frederick J Kaskel4, Michal L Melamed6. 1. Division of Pediatric Nephrology, Children's National Hospital, Washington, DC ddbrown@childrensnational.org. 2. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland ddbrown@childrensnational.org. 4. Division of Pediatric Nephrology, The Children's Hospital at Montefiore, Bronx, New York. 5. Division of Pediatric Nephrology, Weill Cornell Medicine, New York, New York. 6. Department of Medicine, Albert Einstein College of Medicine, Bronx, New York. 7. Division of Pediatric Nephrology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, California. 8. Division of Pediatric Nephrology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 9. Division of Pediatric Nephrology, University of Rochester, Rochester, New York. 10. Division of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, Missouri.
Abstract
BACKGROUND AND OBJECTIVES: Studies of adults have demonstrated an association between metabolic acidosis, as measured by low serum bicarbonate levels, and CKD progression. We evaluated this relationship in children using data from the Chronic Kidney Disease in Children study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship between serum bicarbonate and a composite end point, defined as 50% decline in eGFR or KRT, was described using parametric and semiparametric survival methods. Analyses were stratified by underlying nonglomerular and glomerular diagnoses, and adjusted for demographic characteristics, eGFR, proteinuria, anemia, phosphate, hypertension, and alkali therapy. RESULTS: Six hundred and three participants with nonglomerular disease contributed 2673 person-years of follow-up, and 255 with a glomerular diagnosis contributed 808 person-years of follow-up. At baseline, 39% (237 of 603) of participants with nonglomerular disease had a bicarbonate level of ≤22 meq/L and 36% (85 of 237) of those participants reported alkali therapy treatment. In participants with glomerular disease, 31% (79 of 255) had a bicarbonate of ≤22 meq/L, 18% (14 of 79) of those participants reported alkali therapy treatment. In adjusted longitudinal analyses, compared with participants with a bicarbonate level >22 meq/L, hazard ratios associated with a bicarbonate level of <18 meq/L and 19-22 meq/L were 1.28 [95% confidence interval (95% CI), 0.84 to 1.94] and 0.91 (95% CI, 0.65 to 1.26), respectively, in children with nonglomerular disease. In children with glomerular disease, adjusted hazard ratios associated with bicarbonate level ≤18 meq/L and bicarbonate 19-22 meq/L were 2.16 (95% CI, 1.05 to 4.44) and 1.74 (95% CI, 1.07 to 2.85), respectively. Resolution of low bicarbonate was associated with a lower risk of CKD progression compared with persistently low bicarbonate (≤22 meq/L). CONCLUSIONS: In children with glomerular disease, low bicarbonate was linked to a higher risk of CKD progression. Resolution of low bicarbonate was associated with a lower risk of CKD progression. Fewer than one half of all children with low bicarbonate reported treatment with alkali therapy. Long-term studies of alkali therapy's effect in patients with pediatric CKD are needed.
BACKGROUND AND OBJECTIVES: Studies of adults have demonstrated an association between metabolic acidosis, as measured by low serum bicarbonate levels, and CKD progression. We evaluated this relationship in children using data from the Chronic Kidney Disease in Children study. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The relationship between serum bicarbonate and a composite end point, defined as 50% decline in eGFR or KRT, was described using parametric and semiparametric survival methods. Analyses were stratified by underlying nonglomerular and glomerular diagnoses, and adjusted for demographic characteristics, eGFR, proteinuria, anemia, phosphate, hypertension, and alkali therapy. RESULTS: Six hundred and three participants with nonglomerular disease contributed 2673 person-years of follow-up, and 255 with a glomerular diagnosis contributed 808 person-years of follow-up. At baseline, 39% (237 of 603) of participants with nonglomerular disease had a bicarbonate level of ≤22 meq/L and 36% (85 of 237) of those participants reported alkali therapy treatment. In participants with glomerular disease, 31% (79 of 255) had a bicarbonate of ≤22 meq/L, 18% (14 of 79) of those participants reported alkali therapy treatment. In adjusted longitudinal analyses, compared with participants with a bicarbonate level >22 meq/L, hazard ratios associated with a bicarbonate level of <18 meq/L and 19-22 meq/L were 1.28 [95% confidence interval (95% CI), 0.84 to 1.94] and 0.91 (95% CI, 0.65 to 1.26), respectively, in children with nonglomerular disease. In children with glomerular disease, adjusted hazard ratios associated with bicarbonate level ≤18 meq/L and bicarbonate 19-22 meq/L were 2.16 (95% CI, 1.05 to 4.44) and 1.74 (95% CI, 1.07 to 2.85), respectively. Resolution of low bicarbonate was associated with a lower risk of CKD progression compared with persistently low bicarbonate (≤22 meq/L). CONCLUSIONS: In children with glomerular disease, low bicarbonate was linked to a higher risk of CKD progression. Resolution of low bicarbonate was associated with a lower risk of CKD progression. Fewer than one half of all children with low bicarbonate reported treatment with alkali therapy. Long-term studies of alkali therapy's effect in patients with pediatric CKD are needed.
Authors: Susan L Furth; Chris Pierce; Wun Fung Hui; Colin A White; Craig S Wong; Franz Schaefer; Elke Wühl; Alison G Abraham; Bradley A Warady Journal: Am J Kidney Dis Date: 2018-04-10 Impact factor: 8.860
Authors: Ashutosh Mahajan; Jan Simoni; Simon J Sheather; Kristine R Broglio; M H Rajab; Donald E Wesson Journal: Kidney Int Date: 2010-05-05 Impact factor: 10.612
Authors: Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2017-08-21 Impact factor: 7.124
Authors: Tanushree Banerjee; Deidra C Crews; Donald E Wesson; Anca M Tilea; Rajiv Saran; Nilka Ríos-Burrows; Desmond E Williams; Neil R Powe Journal: J Am Soc Nephrol Date: 2015-02-12 Impact factor: 10.121
Authors: Jérôme Harambat; Kevin Kunzmann; Karolis Azukaitis; Aysun K Bayazit; Nur Canpolat; Anke Doyon; Ali Duzova; Anna Niemirska; Betul Sözeri; Daniela Thurn-Valsassina; Ali Anarat; Lucie Bessenay; Cengiz Candan; Amira Peco-Antic; Alev Yilmaz; Sibylle Tschumi; Sara Testa; Augustina Jankauskiene; Hakan Erdogan; Alejandra Rosales; Harika Alpay; Francesca Lugani; Klaus Arbeiter; Francesca Mencarelli; Aysel Kiyak; Osman Dönmez; Dorota Drozdz; Anette Melk; Uwe Querfeld; Franz Schaefer Journal: Kidney Int Date: 2017-07-18 Impact factor: 10.612
Authors: Elke Wühl; Antonella Trivelli; Stefano Picca; Mieczyslaw Litwin; Amira Peco-Antic; Aleksandra Zurowska; Sara Testa; Augustina Jankauskiene; Sevinc Emre; Alberto Caldas-Afonso; Ali Anarat; Patrick Niaudet; Sevgi Mir; Aysin Bakkaloglu; Barbara Enke; Giovanni Montini; Ann-Margret Wingen; Peter Sallay; Nikola Jeck; Ulla Berg; Salim Caliskan; Simone Wygoda; Katharina Hohbach-Hohenfellner; Jiri Dusek; Tomasz Urasinski; Klaus Arbeiter; Thomas Neuhaus; Jutta Gellermann; Dorota Drozdz; Michel Fischbach; Kristina Möller; Marianne Wigger; Licia Peruzzi; Otto Mehls; Franz Schaefer Journal: N Engl J Med Date: 2009-10-22 Impact factor: 91.245
Authors: Denver D Brown; Megan Carroll; Derek K Ng; Rebecca V Levy; Larry A Greenbaum; Frederick J Kaskel; Susan L Furth; Bradley A Warady; Michal L Melamed; Andrew Dauber Journal: Kidney360 Date: 2022-02-09